Epimedium-Derived Phytoestrogens Benefit Bones

July 11, 2007

1 Min Read
SupplySide Supplement Journal logo in a gray background | SupplySide Supplement Journal

HONG KONGPhytoestrogen flavonoids derived from Epimedium brevicornum maxim may help prevent bone loss in postmenopausal women, without adversely impacting the endometrium. Researchers from the Chinese University of Hong Kong and Shanghai University of Chinese Medicine enrolled 100 healthy older women with a natural menopausal history within 10 to 18 years and a bone mineral density (BMD) T-score at the lumbar spine between -2 and -2.5 SD (standard deviation) in the double blind, placebo-controlled study. The women received a placebo or Epimedium-derived phytoestrogen flavonoids (EPFs) consisting of 60 mg icariin, 15 mg daidzein and 3 mg genistein for 24 months; all participants also received 300 mg/d elemental calcium.

At studys end, BMD had decreased at the femoral neck and lumbar spine in the placebo group, while women taking the EPFs maintained their BMD. Levels of bone biochemical markers did not change in women taking the placebo, while EPF intervention decreased levels of deoxypyridinolineindicating reduced resorptionthough not osteocalcin (marker for bone turnover). Further, neither serum estradiol nor endometrial thickness were changed in either group.

The study was published in the July issue of Journal of Bone and Mineral Research (22:1072-79; DOI:10.1359/jbmr.070405).

Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.

You May Also Like